Trial Profile
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- 29 Jun 2023 Planned End Date changed from 30 Dec 2026 to 30 Dec 2027.
- 29 Jun 2023 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
- 05 Jun 2020 Status changed from active, no longer recruiting to recruiting.